{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T01:43:55Z","timestamp":1794620635074,"version":"4.9.1"},"reference-count":153,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T00:00:00Z","timestamp":1743984000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T00:00:00Z","timestamp":1743984000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1038\/s41571-025-01017-x","type":"journal-article","created":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T13:51:06Z","timestamp":1744033866000},"page":"424-438","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Opportunities and challenges for MRD assessment in the clinical management of multiple myeloma"],"prefix":"10.1038","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1977-3815","authenticated-orcid":false,"given":"Bruno","family":"Paiva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noemi","family":"Puig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria-Teresa","family":"Cedena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Orfao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian G. M.","family":"Durie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7344-9795","authenticated-orcid":false,"given":"Nikhil C.","family":"Munshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9183-4857","authenticated-orcid":false,"given":"Jes\u00fas","family":"San-Miguel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,7]]},"reference":[{"key":"1017_CR1","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1182\/blood.V96.1.355","volume":"96","author":"M Cavo","year":"2000","unstructured":"Cavo, M. et al. Molecular monitoring of minimal residual disease in patients in long-term complete remission after allogeneic stem cell transplantation for multiple myeloma. Blood 96, 355\u2013357 (2000).","journal-title":"Blood"},{"key":"1017_CR2","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1200\/JCO.2000.18.11.2273","volume":"18","author":"G Martinelli","year":"2000","unstructured":"Martinelli, G. et al. Molecular remission after allogeneic or autologous transplantation of hematopoietic stem cells for multiple myeloma. J. Clin. Oncol. 18, 2273\u20132281 (2000).","journal-title":"J. Clin. Oncol."},{"key":"1017_CR3","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1200\/JCO.1999.17.1.208","volume":"17","author":"P Corradini","year":"1999","unstructured":"Corradini, P. et al. Molecular and clinical remissions in multiple myeloma: role of autologous and allogeneic transplantation of hematopoietic cells. J. Clin. Oncol. 17, 208\u2013215 (1999).","journal-title":"J. Clin. Oncol."},{"key":"1017_CR4","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1182\/blood.V87.4.1625.bloodjournal8741625","volume":"87","author":"RM Lemoli","year":"1996","unstructured":"Lemoli, R. M. et al. Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of multiple myeloma patients: positive selection and transplantation of enriched CD34+ cells to remove circulating tumor cells. Blood 87, 1625\u20131634 (1996).","journal-title":"Blood"},{"key":"1017_CR5","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1182\/blood.V85.6.1596.bloodjournal8561596","volume":"85","author":"P Corradini","year":"1995","unstructured":"Corradini, P. et al. High-dose sequential chemoradiotherapy in multiple myeloma: residual tumor cells are detectable in bone marrow and peripheral blood cell harvests and after autografting. Blood 85, 1596\u20131602 (1995).","journal-title":"Blood"},{"key":"1017_CR6","first-page":"651","volume":"12","author":"JM Bird","year":"1993","unstructured":"Bird, J. M., Russell, N. H. & Samson, D. Minimal residual disease after bone marrow transplantation for multiple myeloma: evidence for cure in long-term survivors. Bone Marrow Transpl. 12, 651\u2013654 (1993).","journal-title":"Bone Marrow Transpl."},{"key":"1017_CR7","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1159\/000204846","volume":"85","author":"C Shimazaki","year":"1991","unstructured":"Shimazaki, C. et al. Detection of minimal residual myeloma cells by dual parameter analysis of DNA and cytoplasmic immunoglobulin. Acta Haematol. 85, 20\u201325 (1991).","journal-title":"Acta Haematol."},{"key":"1017_CR8","doi-asserted-by":"publisher","first-page":"4047","DOI":"10.3390\/cancers13164047","volume":"13","author":"IV Kostopoulos","year":"2021","unstructured":"Kostopoulos, I. V. et al. Aberrant plasma cell contamination of peripheral blood stem cell autografts, assessed by next-generation flow cytometry, is a negative predictor for deep response post autologous transplantation in multiple myeloma; a prospective study in 199 patients. Cancers 13, 4047 (2021).","journal-title":"Cancers"},{"key":"1017_CR9","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1002\/jha2.633","volume":"4","author":"R Urushihara","year":"2023","unstructured":"Urushihara, R. et al. Eight-color multiparameter flow cytometry (EuroFlow-NGF) is as sensitive as next-generation sequencing in detecting minimal\/measurable residual disease in autografts of patients with multiple myeloma. EJHaem 4, 184\u2013191 (2023).","journal-title":"EJHaem"},{"key":"1017_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00842-6","volume":"13","author":"O Pasvolsky","year":"2023","unstructured":"Pasvolsky, O. et al. Impact of clonal plasma cells in autografts on outcomes in high-risk multiple myeloma patients. Blood Cancer J. 13, 68 (2023).","journal-title":"Blood Cancer J."},{"key":"1017_CR11","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1002\/ajh.27590","volume":"100","author":"O Venglar","year":"2025","unstructured":"Venglar, O. et al. Level of clonal plasma cells in hematopoietic cell autografts reflects the pre-transplant bone marrow minimal residual disease in multiple myeloma patients. Am. J. Hematol. 100, 704\u2013707 (2025).","journal-title":"Am. J. Hematol."},{"key":"1017_CR12","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/sj.leu.2401348","volume":"13","author":"F Genevieve","year":"1999","unstructured":"Genevieve, F. et al. Evaluation of minimal residual disease by interphase FISH in multiple myeloma: does complete remission exist? Leukemia 13, 641\u2013644 (1999).","journal-title":"Leukemia"},{"key":"1017_CR13","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1046\/j.1365-2141.1999.01685.x","volume":"107","author":"J Almeida","year":"1999","unstructured":"Almeida, J. et al. High-sensitive immunophenotyping and DNA ploidy studies for the investigation of minimal residual disease in multiple myeloma. Br. J. Haematol. 107, 121\u2013131 (1999).","journal-title":"Br. J. Haematol."},{"key":"1017_CR14","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1182\/blood.V99.5.1853","volume":"99","author":"JF San Miguel","year":"2002","unstructured":"San Miguel, J. F. et al. Immunophenotypic evaluation of the plasma cell compartment in multiple myeloma: a tool for comparing the efficacy of different treatment strategies and predicting outcome. Blood 99, 1853\u20131856 (2002).","journal-title":"Blood"},{"key":"1017_CR15","doi-asserted-by":"publisher","first-page":"3095","DOI":"10.1182\/blood-2001-12-0297","volume":"100","author":"AC Rawstron","year":"2002","unstructured":"Rawstron, A. C. et al. Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantation. Blood 100, 3095\u20133100 (2002).","journal-title":"Blood"},{"key":"1017_CR16","first-page":"1365","volume":"90","author":"ME Sarasquete","year":"2005","unstructured":"Sarasquete, M. E. et al. Minimal residual disease monitoring in multiple myeloma: a comparison between allelic-specific oligonucleotide real-time quantitative polymerase chain reaction and flow cytometry. Haematologica 90, 1365\u20131372 (2005).","journal-title":"Haematologica"},{"key":"1017_CR17","first-page":"930","volume":"85","author":"G Martinelli","year":"2000","unstructured":"Martinelli, G. et al. Polymerase chain reaction-based detection of minimal residual disease in multiple myeloma patients receiving allogeneic stem cell transplantation. Haematologica 85, 930\u2013934 (2000).","journal-title":"Haematologica"},{"key":"1017_CR18","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/S1083-8791(00)70006-1","volume":"6","author":"M Ladetto","year":"2000","unstructured":"Ladetto, M. et al. Real-time polymerase chain reaction of immunoglobulin rearrangements for quantitative evaluation of minimal residual disease in multiple myeloma. Biol. Blood Marrow Transpl. 6, 241\u2013253 (2000).","journal-title":"Biol. Blood Marrow Transpl."},{"key":"1017_CR19","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar, S. et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 17, e328\u2013e346 (2016).","journal-title":"Lancet Oncol."},{"key":"1017_CR20","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1111\/bjh.18249","volume":"198","author":"D B\u00f6ckle","year":"2022","unstructured":"B\u00f6ckle, D. et al. Minimal residual disease and imaging-guided consolidation strategies in newly diagnosed and relapsed refractory multiple myeloma. Br. J. Haematol. 198, 515\u2013522 (2022).","journal-title":"Br. J. Haematol."},{"key":"1017_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00820-y","volume":"13","author":"R Bansal","year":"2023","unstructured":"Bansal, R. et al. Prognostic value of early bone marrow MRD status in CAR-T therapy for myeloma. Blood Cancer J. 13, 47 (2023).","journal-title":"Blood Cancer J."},{"key":"1017_CR22","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1158\/2643-3230.BCD-23-0044","volume":"4","author":"B Paiva","year":"2023","unstructured":"Paiva, B. et al. Time-dependent prognostic value of serological and measurable residual disease assessments after idecabtagene vicleucel. Blood Cancer Discov. 4, 365\u2013373 (2023).","journal-title":"Blood Cancer Discov."},{"key":"1017_CR23","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1038\/s41375-018-0329-0","volume":"33","author":"L Rasche","year":"2019","unstructured":"Rasche, L. et al. Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma. Leukemia 33, 1713\u20131722 (2019).","journal-title":"Leukemia"},{"key":"1017_CR24","doi-asserted-by":"publisher","first-page":"e206","DOI":"10.1016\/S1470-2045(17)30189-4","volume":"18","author":"M Cavo","year":"2017","unstructured":"Cavo, M. et al. Role of 18F-FDG PET\/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. Lancet Oncol. 18, e206\u2013e217 (2017).","journal-title":"Lancet Oncol."},{"key":"1017_CR25","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1182\/blood-2022-167382","volume":"140","author":"L Notarfranchi","year":"2022","unstructured":"Notarfranchi, L. et al. Ultra-sensitive assessment of measurable residual disease (MRD) in peripheral blood (PB) of multiple myeloma (MM) patients using bloodflow [abstract]. Blood 140, 2095\u20132097 (2022).","journal-title":"Blood"},{"key":"1017_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01156-x","volume":"14","author":"BA Derman","year":"2024","unstructured":"Derman, B. A. et al. Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP). Blood Cancer J. 14, 170 (2024).","journal-title":"Blood Cancer J."},{"key":"1017_CR27","doi-asserted-by":"publisher","first-page":"2432","DOI":"10.1182\/blood.2024024995","volume":"144","author":"N Puig","year":"2024","unstructured":"Puig, N. et al. Measurable residual disease by mass spectrometry and next-generation flow to assess treatment response in myeloma. Blood 144, 2432\u20132438 (2024).","journal-title":"Blood"},{"key":"1017_CR28","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1200\/JCO.24.00635","volume":"43","author":"M Lasa","year":"2024","unstructured":"Lasa, M. et al. Minimally invasive assessment of peripheral residual disease during maintenance or observation in transplant-eligible patients with multiple myeloma. J. Clin. Oncol. 43, 125\u2013132 (2024).","journal-title":"J. Clin. Oncol."},{"key":"1017_CR29","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1182\/blood-2011-07-370460","volume":"119","author":"B Paiva","year":"2012","unstructured":"Paiva, B. et al. High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma. Blood 119, 687\u2013691 (2012).","journal-title":"Blood"},{"key":"1017_CR30","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1200\/JCO.2011.39.5137","volume":"31","author":"H Ludwig","year":"2013","unstructured":"Ludwig, H. et al. Randomized phase II study of bortezomib, thalidomide, and dexamethasone with or without cyclophosphamide as induction therapy in previously untreated multiple myeloma. J. Clin. Oncol. 31, 247\u2013255 (2013).","journal-title":"J. Clin. Oncol."},{"key":"1017_CR31","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1182\/blood-2018-06-858613","volume":"132","author":"A Perrot","year":"2018","unstructured":"Perrot, A. et al. Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma. Blood 132, 2456\u20132464 (2018).","journal-title":"Blood"},{"key":"1017_CR32","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1182\/blood.2022016782","volume":"141","author":"B Paiva","year":"2023","unstructured":"Paiva, B. et al. MRD dynamics during maintenance for improved prognostication of 1280 patients with myeloma in the TOURMALINE-MM3 and -MM4 trials. Blood 141, 579\u2013591 (2023).","journal-title":"Blood"},{"key":"1017_CR33","doi-asserted-by":"publisher","first-page":"4506","DOI":"10.1182\/bloodadvances.2021006713","volume":"6","author":"T Martin","year":"2022","unstructured":"Martin, T. et al. Depth of response and response kinetics of isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma. Blood Adv. 6, 4506\u20134515 (2022).","journal-title":"Blood Adv."},{"key":"1017_CR34","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1182\/blood.2020010439","volume":"139","author":"J San-Miguel","year":"2022","unstructured":"San-Miguel, J. et al. Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE. Blood 139, 492\u2013501 (2022).","journal-title":"Blood"},{"key":"1017_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00498-0","volume":"11","author":"S Oliva","year":"2021","unstructured":"Oliva, S. et al. Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02\/HOVON 95 MM trial. Blood Cancer J. 11, 106 (2021).","journal-title":"Blood Cancer J."},{"key":"1017_CR36","doi-asserted-by":"publisher","first-page":"e422","DOI":"10.1016\/S2352-3026(21)00130-7","volume":"8","author":"B Diamond","year":"2021","unstructured":"Diamond, B. et al. Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial. Lancet Haematol. 8, e422\u2013e432 (2021).","journal-title":"Lancet Haematol."},{"key":"1017_CR37","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1200\/JCO.20.01814","volume":"39","author":"H Avet-Loiseau","year":"2021","unstructured":"Avet-Loiseau, H. et al. Evaluation of sustained minimal residual disease negativity with daratumumab-combination regimens in relapsed and\/or refractory multiple myeloma: analysis of POLLUX and CASTOR. J. Clin. Oncol. 39, 1139\u20131149 (2021).","journal-title":"J. Clin. Oncol."},{"key":"1017_CR38","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1182\/blood.2020006731","volume":"137","author":"I Goicoechea","year":"2021","unstructured":"Goicoechea, I. et al. Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma. Blood 137, 49\u201360 (2021).","journal-title":"Blood"},{"key":"1017_CR39","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1200\/JCO.19.01231","volume":"38","author":"B Paiva","year":"2020","unstructured":"Paiva, B. et al. Measurable residual disease by next-generation flow cytometry in multiple myeloma. J. Clin. Oncol. 38, 784\u2013792 (2020).","journal-title":"J. Clin. Oncol."},{"key":"1017_CR40","doi-asserted-by":"publisher","first-page":"2900","DOI":"10.1200\/JCO.2016.69.2517","volume":"35","author":"J-J Lahuerta","year":"2017","unstructured":"Lahuerta, J.-J. et al. Depth of response in multiple myeloma: a pooled analysis of three PETHEMA\/GEM clinical trials. J. Clin. Oncol. 35, 2900\u20132910 (2017).","journal-title":"J. Clin. Oncol."},{"key":"1017_CR41","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.1200\/JCO.2012.46.2119","volume":"31","author":"AC Rawstron","year":"2013","unstructured":"Rawstron, A. C. et al. Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the medical research council myeloma IX study. J. Clin. Oncol. 31, 2540\u20132547 (2013).","journal-title":"J. Clin. Oncol."},{"key":"1017_CR42","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1182\/blood-2014-07-590166","volume":"125","author":"AC Rawstron","year":"2015","unstructured":"Rawstron, A. C. et al. Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reduction. Blood 125, 1932\u20131935 (2015).","journal-title":"Blood"},{"key":"1017_CR43","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1182\/bloodadvances.2021005822","volume":"6","author":"M Mohan","year":"2022","unstructured":"Mohan, M. et al. Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma. Blood Adv. 6, 808\u2013817 (2022).","journal-title":"Blood Adv."},{"key":"1017_CR44","doi-asserted-by":"publisher","first-page":"2889","DOI":"10.1200\/JCO.21.02228","volume":"40","author":"RM de Tute","year":"2022","unstructured":"de Tute, R. M. et al. Minimal residual disease after autologous stem-cell transplant for patients with myeloma: prognostic significance and the impact of lenalidomide maintenance and molecular risk. J. Clin. Oncol. 40, 2889\u20132900 (2022).","journal-title":"J. Clin. Oncol."},{"key":"1017_CR45","doi-asserted-by":"publisher","first-page":"2757","DOI":"10.1200\/JCO.23.00934","volume":"42","author":"MC Pasquini","year":"2024","unstructured":"Pasquini, M. C. et al. Minimal residual disease status in multiple myeloma 1 year after autologous hematopoietic cell transplantation and lenalidomide maintenance are associated with long-term overall survival. J. Clin. Oncol. 42, 2757\u20132768 (2024).","journal-title":"J. Clin. Oncol."},{"key":"1017_CR46","doi-asserted-by":"publisher","unstructured":"Landgren, O. et al. Safety and effectiveness of weekly carfilzomib, lenalidomide, dexamethasone, and daratumumab combination therapy for patients with newly diagnosed multiple myeloma: the MANHATTAN nonrandomized clinical trial. JAMA Oncol. https:\/\/doi.org\/10.1001\/jamaoncol.2021.0611 (2021).","DOI":"10.1001\/jamaoncol.2021.0611"},{"key":"1017_CR47","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/JCO.2017.73.1331","volume":"35","author":"JL Harousseau","year":"2017","unstructured":"Harousseau, J. L. & Avet-Loiseau, H. Minimal residual disease negativity is a new end point of myeloma therapy. J. Clin. Oncol. 35, 2863\u20132865 (2017).","journal-title":"J. Clin. Oncol."},{"key":"1017_CR48","doi-asserted-by":"publisher","first-page":"3247","DOI":"10.1200\/JCO.23.02771","volume":"42","author":"M-V Mateos","year":"2024","unstructured":"Mateos, M.-V. et al. Curative strategy for high-risk smoldering myeloma: carfilzomib, lenalidomide, and dexamethasone (KRd) followed by transplant, KRd consolidation, and Rd maintenance. J. Clin. Oncol. 42, 3247\u20133256 (2024).","journal-title":"J. Clin. Oncol."},{"key":"1017_CR49","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1001\/jamaoncol.2021.3971","volume":"7","author":"D Kazandjian","year":"2021","unstructured":"Kazandjian, D. et al. Carfilzomib, lenalidomide, and dexamethasone followed by lenalidomide maintenance for prevention of symptomatic multiple myeloma in patients with high-risk smoldering myeloma: a phase 2 nonrandomized controlled trial. JAMA Oncol. 7, 1678\u20131685 (2021).","journal-title":"JAMA Oncol."},{"key":"1017_CR50","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1200\/JCO.23.01696","volume":"42","author":"LB Leypoldt","year":"2024","unstructured":"Leypoldt, L. B. et al. Isatuximab, carfilzomib, lenalidomide, and dexamethasone for the treatment of high-risk newly diagnosed multiple myeloma. J. Clin. Oncol. 42, 26\u201337 (2024).","journal-title":"J. Clin. Oncol."},{"key":"1017_CR51","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1182\/blood.2022019531","volume":"142","author":"L Rosi\u00f1ol","year":"2023","unstructured":"Rosi\u00f1ol, L. et al. Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myeloma. Blood 142, 1518\u20131528 (2023).","journal-title":"Blood"},{"key":"1017_CR52","doi-asserted-by":"publisher","first-page":"2901","DOI":"10.1200\/JCO.21.01935","volume":"40","author":"LJ Costa","year":"2022","unstructured":"Costa, L. J. et al. Daratumumab, carfilzomib, lenalidomide, and dexamethasone with minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma. J. Clin. Oncol. 40, 2901\u20132912 (2022).","journal-title":"J. Clin. Oncol."},{"key":"1017_CR53","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1182\/blood.2024024371","volume":"144","author":"O Landgren","year":"2024","unstructured":"Landgren, O. et al. EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical end point for multiple myeloma. Blood 144, 359\u2013367 (2024).","journal-title":"Blood"},{"key":"1017_CR54","doi-asserted-by":"publisher","unstructured":"Shi, Q. et al. Minimal residual disease-based end point for accelerated assessment of clinical trials in multiple myeloma: a pooled analysis of individual patient data from multiple randomized trials. J. Clin. Oncol. https:\/\/doi.org\/10.1200\/JCO-24-02020 (2025).","DOI":"10.1200\/JCO-24-02020"},{"key":"1017_CR55","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1182\/blood.2021012319","volume":"138","author":"A Jim\u00e9nez-Ubieto","year":"2021","unstructured":"Jim\u00e9nez-Ubieto, A. et al. Validation of the International Myeloma Working Group standard response criteria in the PETHEMA\/GEM2012MENOS65 study: are these times of change? Blood 138, 1901\u20131905 (2021).","journal-title":"Blood"},{"key":"1017_CR56","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0237155","volume":"15","author":"M-T Cedena","year":"2020","unstructured":"Cedena, M.-T. et al. The clinical significance of stringent complete response in multiple myeloma is surpassed by minimal residual disease measurements. PLoS ONE 15, e0237155 (2020).","journal-title":"PLoS ONE"},{"key":"1017_CR57","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1182\/blood-2015-04-638742","volume":"126","author":"J Mart\u00ednez-L\u00f3pez","year":"2015","unstructured":"Mart\u00ednez-L\u00f3pez, J. et al. Critical analysis of the stringent complete response in multiple myeloma: contribution of sFLC and bone marrow clonality. Blood 126, 858\u2013862 (2015).","journal-title":"Blood"},{"key":"1017_CR58","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-00363-6","volume":"10","author":"MA Tschautscher","year":"2020","unstructured":"Tschautscher, M. A. et al. Utility of repeating bone marrow biopsy for confirmation of complete response in multiple myeloma. Blood Cancer J. 10, 95 (2020).","journal-title":"Blood Cancer J."},{"key":"1017_CR59","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1182\/blood-2024-210198","volume":"144","author":"N Puig","year":"2024","unstructured":"Puig, N. et al. Reevaluating the IMWG multiple myeloma complete response criterion in the era of mass spectrometry: a critical analysis [abstract]. Blood 144, 489 (2024).","journal-title":"Blood"},{"key":"1017_CR60","doi-asserted-by":"publisher","first-page":"5775","DOI":"10.1200\/JCO.2008.17.9721","volume":"26","author":"JJ Lahuerta","year":"2008","unstructured":"Lahuerta, J. J. et al. Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival. J. Clin. Oncol. 26, 5775\u20135782 (2008).","journal-title":"J. Clin. Oncol."},{"key":"1017_CR61","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1111\/ejh.12829","volume":"98","author":"H van de Velde","year":"2017","unstructured":"van de Velde, H. et al. Association between complete response and outcomes in transplant-eligible myeloma patients in the era of novel agents. Eur. J. Haematol. 98, 269\u2013279 (2017).","journal-title":"Eur. J. Haematol."},{"key":"1017_CR62","doi-asserted-by":"publisher","first-page":"4691","DOI":"10.1182\/blood-2010-10-299487","volume":"117","author":"SV Rajkumar","year":"2011","unstructured":"Rajkumar, S. V. et al. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood 117, 4691\u20134695 (2011).","journal-title":"Blood"},{"key":"1017_CR63","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","volume":"20","author":"BGM Durie","year":"2006","unstructured":"Durie, B. G. M. et al. International uniform response criteria for multiple myeloma. Leukemia 20, 1467\u20131473 (2006).","journal-title":"Leukemia"},{"key":"1017_CR64","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1046\/j.1365-2141.1998.00930.x","volume":"102","author":"J Blad\u00e9","year":"1998","unstructured":"Blad\u00e9, J. et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br. J. Haematol. 102, 1115\u20131123 (1998).","journal-title":"Br. J. Haematol."},{"key":"1017_CR65","doi-asserted-by":"publisher","first-page":"4017","DOI":"10.1182\/blood-2008-05-159624","volume":"112","author":"B Paiva","year":"2008","unstructured":"Paiva, B. et al. Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood 112, 4017\u20134023 (2008).","journal-title":"Blood"},{"key":"1017_CR66","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1200\/JCO.2009.23.7172","volume":"28","author":"M Ladetto","year":"2010","unstructured":"Ladetto, M. et al. Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma. J. Clin. Oncol. 28, 2077\u20132084 (2010).","journal-title":"J. Clin. Oncol."},{"key":"1017_CR67","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1182\/blood-2018-09-874396","volume":"133","author":"T Facon","year":"2019","unstructured":"Facon, T. et al. Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma. Blood 133, 1953\u20131963 (2019).","journal-title":"Blood"},{"key":"1017_CR68","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1182\/blood.2021011101","volume":"139","author":"M Cavo","year":"2021","unstructured":"Cavo, M. et al. Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, MAIA. Blood 139, 835\u2013844 (2021).","journal-title":"Blood"},{"key":"1017_CR69","doi-asserted-by":"publisher","first-page":"2389","DOI":"10.1182\/blood.2024024582","volume":"144","author":"S Ailawadhi","year":"2024","unstructured":"Ailawadhi, S. et al. Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses. Blood 144, 2389\u20132401 (2024).","journal-title":"Blood"},{"key":"1017_CR70","doi-asserted-by":"publisher","first-page":"5988","DOI":"10.1182\/bloodadvances.2020002827","volume":"4","author":"NC Munshi","year":"2020","unstructured":"Munshi, N. C. et al. A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma. Blood Adv. 4, 5988\u20135999 (2020).","journal-title":"Blood Adv."},{"key":"1017_CR71","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1056\/NEJMoa2312054","volume":"390","author":"P Sonneveld","year":"2024","unstructured":"Sonneveld, P. et al. Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. N. Engl. J. Med. 390, 301\u2013313 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1017_CR72","doi-asserted-by":"publisher","unstructured":"Mai, E. K. et al. Isatuximab, lenalidomide, bortezomib, and dexamethasone induction therapy for transplant-eligible newly diagnosed multiple myeloma: final part 1 analysis of the GMMG-HD7 trial. J. Clin. Oncol. https:\/\/doi.org\/10.1200\/JCO-24-02266 (2024).","DOI":"10.1200\/JCO-24-02266"},{"key":"1017_CR73","doi-asserted-by":"publisher","unstructured":"Zabaleta, A. et al. Clinical significance of complete remission and measurable residual disease in relapsed\/refractory multiple myeloma patients treated with T-cell redirecting immunotherapy. Am. J. Hematol. https:\/\/doi.org\/10.1002\/ajh.27526 (2024).","DOI":"10.1002\/ajh.27526"},{"key":"1017_CR74","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1182\/blood-2024-200871","volume":"144","author":"S Zweegman","year":"2024","unstructured":"Zweegman, S. et al. Phase 3 randomized study of daratumumab (DARA) + bortezomib, lenalidomide and dexamethasone (VRd) versus alone in patients with transplant-ineligible newly diagnosed multiple myeloma or for whom transplant is not planned as initial therapy: analysis of minimal residual disease in the Cepheus trial [abstract]. Blood 144, 362 (2024).","journal-title":"Blood"},{"key":"1017_CR75","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1182\/blood-2024-203818","volume":"144","author":"RZ Orlowski","year":"2024","unstructured":"Orlowski, R. Z. et al. Isatuximab, bortezomib, lenalidomide, and dexamethasone (Isa-VRd) in patients with newly diagnosed multiple myeloma (NDMM): analyses of minimal residual disease (MRD) negativity dynamics in the phase 3 Imroz study [abstract]. Blood 144, 770 (2024).","journal-title":"Blood"},{"key":"1017_CR76","doi-asserted-by":"publisher","first-page":"e53","DOI":"10.3324\/haematol.2014.115162","volume":"100","author":"B Paiva","year":"2015","unstructured":"Paiva, B. et al. The prognostic value of multiparameter flow cytometry minimal residual disease assessment in relapsed multiple myeloma. Haematologica 100, e53\u2013e55 (2015).","journal-title":"Haematologica"},{"key":"1017_CR77","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1200\/JCO.2010.33.1967","volume":"29","author":"B Paiva","year":"2011","unstructured":"Paiva, B. et al. Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma. J. Clin. Oncol. 29, 1627\u20131633 (2011).","journal-title":"J. Clin. Oncol."},{"key":"1017_CR78","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1001\/jamaoncol.2015.2010","volume":"1","author":"N Korde","year":"2015","unstructured":"Korde, N. et al. Treatment with carfilzomib-lenalidomide-dexamethasone with lenalidomide extension in patients with smoldering or newly diagnosed multiple myeloma. JAMA Oncol. 1, 746\u2013754 (2015).","journal-title":"JAMA Oncol."},{"key":"1017_CR79","doi-asserted-by":"publisher","first-page":"102016","DOI":"10.1016\/j.eclinm.2023.102016","volume":"60","author":"S Oliva","year":"2023","unstructured":"Oliva, S. et al. Prospective evaluation of minimal residual disease in the phase II FORTE trial: a head-to-head comparison between multiparameter flow cytometry and next-generation sequencing. eClinicalMedicine 60, 102016 (2023).","journal-title":"eClinicalMedicine"},{"key":"1017_CR80","doi-asserted-by":"publisher","first-page":"3165","DOI":"10.1182\/blood-2016-03-705319","volume":"127","author":"B Paiva","year":"2016","unstructured":"Paiva, B. et al. Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients. Blood 127, 3165\u20133174 (2016).","journal-title":"Blood"},{"key":"1017_CR81","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1182\/bloodadvances.2016003715","volume":"1","author":"M Roshal","year":"2017","unstructured":"Roshal, M. et al. MRD detection in multiple myeloma: comparison between MSKCC 10-color single-tube and EuroFlow 8-color 2-tube methods. Blood Adv. 1, 728\u2013732 (2017).","journal-title":"Blood Adv."},{"key":"1017_CR82","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00418-2","volume":"11","author":"BA Derman","year":"2021","unstructured":"Derman, B. A. et al. Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantation. Blood Cancer J. 11, 19 (2021).","journal-title":"Blood Cancer J."},{"key":"1017_CR83","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1038\/leu.2017.58","volume":"31","author":"J Martinez-Lopez","year":"2017","unstructured":"Martinez-Lopez, J. et al. Analytical and clinical validation of a novel in-house deep-sequencing method for minimal residual disease monitoring in a phase II trial for multiple myeloma. Leukemia 31, 1446\u20131449 (2017).","journal-title":"Leukemia"},{"key":"1017_CR84","doi-asserted-by":"publisher","first-page":"3073","DOI":"10.1182\/blood-2014-01-550020","volume":"123","author":"J Martinez-Lopez","year":"2014","unstructured":"Martinez-Lopez, J. et al. Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma. Blood 123, 3073\u20133079 (2014).","journal-title":"Blood"},{"key":"1017_CR85","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/leu.2013.217","volume":"28","author":"N Puig","year":"2014","unstructured":"Puig, N. et al. Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry. Leukemia 28, 391\u2013397 (2014).","journal-title":"Leukemia"},{"key":"1017_CR86","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1038\/leu.2017.29","volume":"31","author":"J Flores-Montero","year":"2017","unstructured":"Flores-Montero, J. et al. Next generation flow (NGF) for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. Leukemia 31, 2094\u20132103 (2017).","journal-title":"Leukemia"},{"key":"1017_CR87","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-00377-0","volume":"10","author":"A Medina","year":"2020","unstructured":"Medina, A. et al. Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma. Blood Cancer J. 10, 108 (2020).","journal-title":"Blood Cancer J."},{"key":"1017_CR88","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1002\/ajh.27484","volume":"99","author":"D Jevremovic","year":"2024","unstructured":"Jevremovic, D. et al. FDA IDE validation of multiple myeloma MRD test by flow cytometry. Am. J. Hematol. 99, 2399\u20132401 (2024).","journal-title":"Am. J. Hematol."},{"key":"1017_CR89","doi-asserted-by":"publisher","first-page":"e810","DOI":"10.1016\/S2352-3026(22)00263-0","volume":"9","author":"H Goldschmidt","year":"2022","unstructured":"Goldschmidt, H. et al. Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase. Lancet Haematol. 9, e810\u2013e821 (2022).","journal-title":"Lancet Haematol."},{"key":"1017_CR90","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000300","volume":"3","author":"E Terpos","year":"2019","unstructured":"Terpos, E. et al. Impact of minimal residual disease detection by next-generation flow cytometry in multiple myeloma patients with sustained complete remission after frontline therapy. Hemasphere 3, e300 (2019).","journal-title":"Hemasphere"},{"key":"1017_CR91","doi-asserted-by":"publisher","first-page":"E60","DOI":"10.1002\/ajh.25702","volume":"95","author":"M Tschautscher","year":"2020","unstructured":"Tschautscher, M. et al. Implications and outcomes of MRD-negative multiple myeloma patients with immunofixation positivity. Am. J. Hematol. 95, E60\u2013E62 (2020).","journal-title":"Am. J. Hematol."},{"key":"1017_CR92","doi-asserted-by":"publisher","first-page":"4924","DOI":"10.3390\/cancers13194924","volume":"13","author":"N Puig","year":"2021","unstructured":"Puig, N. et al. Reference values to assess hemodilution and warn of potential false-negative minimal residual disease results in myeloma. Cancers 13, 4924 (2021).","journal-title":"Cancers"},{"key":"1017_CR93","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00951-2","volume":"13","author":"J\u00de \u00d3skarsson","year":"2023","unstructured":"\u00d3skarsson, J. \u00de et al. Determining hemodilution in diagnostic bone marrow aspirated samples in plasma cell disorders by next-generation flow cytometry: Proposal for a bone marrow quality index. Blood Cancer J. 13, 177 (2023).","journal-title":"Blood Cancer J."},{"key":"1017_CR94","unstructured":"Food and Drug Administration. FDA authorizes first next generation sequencing-based test to detect very low levels of remaining cancer cells in patients with acute lymphoblastic leukemia or multiple myeloma. FDA https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-authorizes-first-next-generation-sequencing-based-test-detect-very-low-levels-remaining-cancer (2018)."},{"key":"1017_CR95","unstructured":"Oncologic Drugs Advisory Committee (ODAC). i2TEAMM presentation to support MRD as accelerated approval endpoint. FDA https:\/\/www.fda.gov\/media\/177738\/download (2024)."},{"key":"1017_CR96","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00794-x","volume":"13","author":"R Fonseca","year":"2023","unstructured":"Fonseca, R. et al. Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patients. Blood Cancer J. 13, 32 (2023).","journal-title":"Blood Cancer J."},{"key":"1017_CR97","doi-asserted-by":"publisher","first-page":"3295","DOI":"10.1182\/bloodadvances.2020002037","volume":"4","author":"J Martinez-Lopez","year":"2020","unstructured":"Martinez-Lopez, J. et al. Clinical value of measurable residual disease testing for assessing depth, duration, and direction of response in multiple myeloma. Blood Adv. 4, 3295\u20133301 (2020).","journal-title":"Blood Adv."},{"key":"1017_CR98","doi-asserted-by":"publisher","first-page":"e302","DOI":"10.1016\/S1470-2045(19)30309-2","volume":"20","author":"J Hillengass","year":"2019","unstructured":"Hillengass, J. et al. International Myeloma Working Group consensus recommendations on imaging in monoclonal plasma cell disorders. Lancet Oncol. 20, e302\u2013e312 (2019).","journal-title":"Lancet Oncol."},{"key":"1017_CR99","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1200\/JCO.20.00386","volume":"39","author":"E Zamagni","year":"2021","unstructured":"Zamagni, E. et al. Standardization of 18F-FDG-PET\/CT according to Deauville criteria for metabolic complete response definition in newly diagnosed multiple myeloma. J. Clin. Oncol. 39, 116\u2013125 (2021).","journal-title":"J. Clin. Oncol."},{"key":"1017_CR100","doi-asserted-by":"publisher","first-page":"2911","DOI":"10.1200\/JCO.2017.72.2975","volume":"35","author":"P Moreau","year":"2017","unstructured":"Moreau, P. et al. Prospective evaluation of magnetic resonance imaging and [18F]fluorodeoxyglucose positron emission tomography-computed tomography at diagnosis and before maintenance therapy in symptomatic patients with multiple myeloma included in the IFM\/DFCI 2009 trial: results of the IMAJEM study. J. Clin. Oncol. 35, 2911\u20132918 (2017).","journal-title":"J. Clin. Oncol."},{"key":"1017_CR101","doi-asserted-by":"publisher","first-page":"621","DOI":"10.3324\/haematol.2021.280051","volume":"108","author":"F Kraeber-Bod\u00e9r\u00e9","year":"2023","unstructured":"Kraeber-Bod\u00e9r\u00e9, F. et al. Prognostic value of positron emission tomography\/computed tomography in transplant-eligible newly diagnosed multiple myeloma patients from CASSIOPEIA: the CASSIOPET study. Haematologica 108, 621\u2013626 (2023).","journal-title":"Haematologica"},{"key":"1017_CR102","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1182\/blood-2009-03-213280","volume":"114","author":"TB Bartel","year":"2009","unstructured":"Bartel, T. B. et al. F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. Blood 114, 2068\u20132076 (2009).","journal-title":"Blood"},{"key":"1017_CR103","doi-asserted-by":"publisher","first-page":"102017","DOI":"10.1016\/j.eclinm.2023.102017","volume":"60","author":"E Zamagni","year":"2023","unstructured":"Zamagni, E. et al. Impact of minimal residual disease standardised assessment by FDG-PET\/CT in transplant-eligible patients with newly diagnosed multiple myeloma enrolled in the imaging sub-study of the FORTE trial. eClinicalMedicine 60, 102017 (2023).","journal-title":"eClinicalMedicine"},{"key":"1017_CR104","doi-asserted-by":"publisher","first-page":"5989","DOI":"10.1182\/blood-2011-06-361386","volume":"118","author":"E Zamagni","year":"2011","unstructured":"Zamagni, E. et al. Prognostic relevance of 18-F FDG PET\/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. Blood 118, 5989\u20135995 (2011).","journal-title":"Blood"},{"key":"1017_CR105","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.1182\/bloodadvances.2020004131","volume":"5","author":"M Kaddoura","year":"2021","unstructured":"Kaddoura, M. et al. Prognostic impact of posttransplant FDG PET\/CT scan in multiple myeloma. Blood Adv. 5, 2753\u20132759 (2021).","journal-title":"Blood Adv."},{"key":"1017_CR106","doi-asserted-by":"publisher","unstructured":"Sanoja-Flores, L. et al. Blood monitoring of circulating tumor plasma cells by next generation flow in multiple myeloma after therapy. Blood https:\/\/doi.org\/10.1182\/blood.2019002610 (2019).","DOI":"10.1182\/blood.2019002610"},{"key":"1017_CR107","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1016\/j.bbmt.2018.02.017","volume":"24","author":"AJ Cowan","year":"2018","unstructured":"Cowan, A. J. et al. Circulating plasma cells at the time of collection of autologous PBSC for transplant in multiple myeloma patients is a negative prognostic factor even in the age of post-transplant maintenance therapy. Biol. Blood Marrow Transpl. 24, 1386\u20131391 (2018).","journal-title":"Biol. Blood Marrow Transpl."},{"key":"1017_CR108","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1038\/s41409-018-0245-y","volume":"53","author":"I Moor","year":"2018","unstructured":"Moor, I. et al. Peripheral flow-MRD status at the time of autologous stem cell collection predicts outcome in multiple myeloma. Bone Marrow Transpl. 53, 1599\u20131602 (2018).","journal-title":"Bone Marrow Transpl."},{"key":"1017_CR109","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2016.117","volume":"6","author":"R Chakraborty","year":"2016","unstructured":"Chakraborty, R. et al. Risk stratification in myeloma by detection of circulating plasma cells prior to autologous stem cell transplantation in the novel agent era. Blood Cancer J. 6, e512 (2016).","journal-title":"Blood Cancer J."},{"key":"1017_CR110","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.63","volume":"8","author":"PR Tembhare","year":"2024","unstructured":"Tembhare, P. R. et al. Circulating tumor plasma cells and peripheral blood measurable residual disease assessment in multiple myeloma patients not planned for upfront transplant. Hemasphere 8, e63 (2024).","journal-title":"Hemasphere"},{"key":"1017_CR111","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1182\/blood.2023022540","volume":"143","author":"Y Kogure","year":"2024","unstructured":"Kogure, Y. et al. ctDNA improves prognostic prediction for patients with relapsed\/refractory MM receiving ixazomib, lenalidomide, and dexamethasone. Blood 143, 2401\u20132413 (2024).","journal-title":"Blood"},{"key":"1017_CR112","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.3324\/haematol.2016.161414","volume":"102","author":"A Oberle","year":"2017","unstructured":"Oberle, A. et al. Monitoring multiple myeloma by next-generation sequencing of V(D)J rearrangements from circulating myeloma cells and cell-free myeloma DNA. Haematologica 102, 1105\u20131111 (2017).","journal-title":"Haematologica"},{"key":"1017_CR113","doi-asserted-by":"publisher","first-page":"2811","DOI":"10.1182\/bloodadvances.2018025197","volume":"2","author":"C Mazzotti","year":"2018","unstructured":"Mazzotti, C. et al. Myeloma MRD by deep sequencing from circulating tumor DNA does not correlate with results obtained in the bone marrow. Blood Adv. 2, 2811\u20132813 (2018).","journal-title":"Blood Adv."},{"key":"1017_CR114","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.hoc.2023.12.009","volume":"38","author":"BA Derman","year":"2024","unstructured":"Derman, B. A. & Fonseca, R. Measurable residual disease and decision-making in multiple myeloma. Hematol. Oncol. Clin. North. Am. 38, 477\u2013495 (2024).","journal-title":"Hematol. Oncol. Clin. North. Am."},{"key":"1017_CR115","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00624-6","volume":"12","author":"A Dispenzieri","year":"2022","unstructured":"Dispenzieri, A. et al. Mass-fix better predicts for PFS and OS than standard methods among multiple myeloma patients participating on the STAMINA trial (BMT CTN 0702\/07LT). Blood Cancer J. 12, 27 (2022).","journal-title":"Blood Cancer J."},{"key":"1017_CR116","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1182\/blood.2024024041","volume":"144","author":"T Kubicki","year":"2024","unstructured":"Kubicki, T. et al. Mass spectrometry-based assessment of M protein in peripheral blood during maintenance therapy in multiple myeloma. Blood 144, 955\u2013963 (2024).","journal-title":"Blood"},{"key":"1017_CR117","doi-asserted-by":"publisher","unstructured":"Puig, N. et al. Single-point and kinetics of peripheral residual disease by mass spectrometry to predict outcome in patients with high risk smoldering multiple myeloma included in the GEM-CESAR trial. Haematologica https:\/\/doi.org\/10.3324\/haematol.2024.285742 (2024).","DOI":"10.3324\/haematol.2024.285742"},{"key":"1017_CR118","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1182\/blood-2024-209748","volume":"144","author":"N Puig","year":"2024","unstructured":"Puig, N. et al. Clinical value of peripheral residual disease (PRD) and measurable residual disease (MRD) in newly diagnosed elderly patients in the GEM2017FIT trial [abstrract]. Blood 144, 365 (2024).","journal-title":"Blood"},{"key":"1017_CR119","doi-asserted-by":"publisher","unstructured":"Zhao, J. et al. Comparison of EasyM, a clonotypic mass spectrometry assay, and EuroFlow minimal residual disease assessment in multiple myeloma. Haematologica https:\/\/doi.org\/10.3324\/haematol.2024.285933 (2024).","DOI":"10.3324\/haematol.2024.285933"},{"key":"1017_CR120","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00408-4","volume":"11","author":"DL Murray","year":"2021","unstructured":"Murray, D. L. et al. Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee Report. Blood Cancer J. 11, 24 (2021).","journal-title":"Blood Cancer J."},{"key":"1017_CR121","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1182\/blood-2023-186916","volume":"142","author":"C Gonzalez","year":"2023","unstructured":"Gonzalez, C. et al. Minimally invasive assessment of measurable residual disease (MRD) in multiple myeloma (MM) [abstract]. Blood 142, 339 (2023).","journal-title":"Blood"},{"key":"1017_CR122","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1182\/blood-2024-210899","volume":"144","author":"EA Dean","year":"2024","unstructured":"Dean, E. A. et al. Soluble B-cell maturation antigen as a serum marker of minimal residual disease in patients with multiple myeloma [abstract]. Blood 144, 1968 (2024).","journal-title":"Blood"},{"key":"1017_CR123","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/s41375-019-0588-4","volume":"34","author":"J-J Garc\u00e9s","year":"2020","unstructured":"Garc\u00e9s, J.-J. et al. Transcriptional profiling of circulating tumor cells in multiple myeloma: a new model to understand disease dissemination. Leukemia 34, 589\u2013603 (2020).","journal-title":"Leukemia"},{"key":"1017_CR124","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1182\/blood.2023022083","volume":"143","author":"C Guerrero","year":"2024","unstructured":"Guerrero, C. et al. Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myeloma. Blood 143, 597\u2013603 (2024).","journal-title":"Blood"},{"key":"1017_CR125","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1182\/blood.2023022080","volume":"143","author":"M D\u2019Agostino","year":"2024","unstructured":"D\u2019Agostino, M. et al. Predictors of unsustained measurable residual disease negativity in patients with multiple myeloma. Blood 143, 592\u2013596 (2024).","journal-title":"Blood"},{"key":"1017_CR126","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s41375-020-01012-4","volume":"35","author":"LJ Costa","year":"2021","unstructured":"Costa, L. J. et al. International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials. Leukemia 35, 18\u201330 (2021).","journal-title":"Leukemia"},{"key":"1017_CR127","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1182\/blood-2020-136258","volume":"136","author":"S Rodr\u00edguez","year":"2020","unstructured":"Rodr\u00edguez, S. et al. Discordances between immunofixation (IFx) and minimal residual disease (MRD) assessment with next-generation flow (NGF) and sequencing (NGS) in patients (Pts) with multiple myeloma (MM): clinical and pathogenic significance [abstract]. Blood 136, 5\u20136 (2020).","journal-title":"Blood"},{"key":"1017_CR128","doi-asserted-by":"publisher","unstructured":"Paiva, B., San-Miguel, J. F. & Avet-Loiseau, H. MRD in multiple myeloma: does CR really matter? Blood https:\/\/doi.org\/10.1182\/blood.2022016170 (2022).","DOI":"10.1182\/blood.2022016170"},{"key":"1017_CR129","doi-asserted-by":"publisher","first-page":"e890","DOI":"10.1016\/S2352-3026(23)00236-3","volume":"10","author":"LJ Costa","year":"2023","unstructured":"Costa, L. J. et al. Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial. Lancet Haematol. 10, e890\u2013e901 (2023).","journal-title":"Lancet Haematol."},{"key":"1017_CR130","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1182\/blood-2023-185661","volume":"142","author":"C Guerrero","year":"2023","unstructured":"Guerrero, C. et al. Kinetics and biology of circulating tumor cells (CTCs) and measurable residual disease (MRD): two dynamic high-risk clones in multiple myeloma (MM) [abstract]. Blood 142, 871 (2023).","journal-title":"Blood"},{"key":"1017_CR131","unstructured":"Food and Drug Administration. Oncologic Drugs Advisory Committee Meeting: Use of minimal residual disease (MRD) as an endpoint in multiple myeloma clinical trials. FDA https:\/\/www.fda.gov\/media\/177652\/download (2024)."},{"key":"1017_CR132","unstructured":"Seymour, C. FDA\u2019s ODAC recognizes MRD as an accepted end point for accelerated approval in multiple myeloma. OncLive https:\/\/www.onclive.com\/view\/fda-s-odac-recognizes-mrd-as-an-accepted-end-point-for-accelerated-approval-in-multiple-myeloma (2024)."},{"key":"1017_CR133","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1182\/bloodadvances.2023010821","volume":"8","author":"B Paiva","year":"2024","unstructured":"Paiva, B. et al. Impact of treatment effect on MRD and PFS: an aggregate data analysis from randomized clinical trials in multiple myeloma. Blood Adv. 8, 219\u2013223 (2024).","journal-title":"Blood Adv."},{"key":"1017_CR134","doi-asserted-by":"publisher","first-page":"7502","DOI":"10.1200\/JCO.2024.42.16_suppl.7502","volume":"42","author":"P Rodr\u00edguez-Otero","year":"2024","unstructured":"Rodr\u00edguez-Otero, P. et al. Daratumumab (DARA) + bortezomib\/lenalidomide\/dexamethasone (VRd) in transplant-eligible (TE) patients (pts) with newly diagnosed multiple myeloma (NDMM): analysis of minimal residual disease (MRD) in the PERSEUS trial [abstract]. J. Clin. Oncol. 42, 7502 (2024).","journal-title":"J. Clin. Oncol."},{"key":"1017_CR135","first-page":"2598","volume":"28","author":"AZ Badros","year":"2024","unstructured":"Badros, A. Z. et al. Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA study. Blood 28, 2598\u20132609 (2024).","journal-title":"Blood"},{"key":"1017_CR136","doi-asserted-by":"publisher","unstructured":"Guerrero, C. et al. A machine learning model based on tumor and immune biomarkers to predict undetectable MRD and survival outcomes in multiple myeloma. Clin. Cancer Res. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-3430 (2022).","DOI":"10.1158\/1078-0432.CCR-21-3430"},{"key":"1017_CR137","doi-asserted-by":"publisher","first-page":"3245","DOI":"10.3390\/cancers12113245","volume":"12","author":"K Papadimitriou","year":"2020","unstructured":"Papadimitriou, K. et al. Deep phenotyping reveals distinct immune signatures correlating with prognostication, treatment responses, and MRD status in multiple myeloma. Cancers 12, 3245 (2020).","journal-title":"Cancers"},{"key":"1017_CR138","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-40966-8","volume":"14","author":"DG Coffey","year":"2023","unstructured":"Coffey, D. G. et al. Immunophenotypic correlates of sustained MRD negativity in patients with multiple myeloma. Nat. Commun. 14, 5335 (2023).","journal-title":"Nat. Commun."},{"key":"1017_CR139","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.bbmt.2017.01.076","volume":"23","author":"R Chakraborty","year":"2017","unstructured":"Chakraborty, R. et al. Impact of post-transplant response and minimal residual disease on survival in myeloma with high-risk cytogenetics. Biol. Blood Marrow Transpl. 23, 598\u2013605 (2017).","journal-title":"Biol. Blood Marrow Transpl."},{"key":"1017_CR140","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1038\/s41409-020-0791-y","volume":"55","author":"DA Patel","year":"2020","unstructured":"Patel, D. A. et al. Minimal residual disease negativity and lenalidomide maintenance therapy are associated with superior survival outcomes in multiple myeloma. Bone Marrow Transpl. 55, 1137\u20131146 (2020).","journal-title":"Bone Marrow Transpl."},{"key":"1017_CR141","doi-asserted-by":"publisher","unstructured":"Muronova, L. et al. Real-world evidence on prognostic value of MRD in multiple myeloma using flow cytometry. Eur. J. Haematol. https:\/\/doi.org\/10.1111\/ejh.14316 (2025).","DOI":"10.1111\/ejh.14316"},{"key":"1017_CR142","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1182\/bloodadvances.2020001508","volume":"4","author":"R Alonso","year":"2020","unstructured":"Alonso, R. et al. Prolonged lenalidomide maintenance therapy improves the depth of response in multiple myeloma. Blood Adv. 4, 2163\u20132171 (2020).","journal-title":"Blood Adv."},{"key":"1017_CR143","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s13045-021-01135-w","volume":"14","author":"J Martinez-Lopez","year":"2021","unstructured":"Martinez-Lopez, J. et al. Making clinical decisions based on measurable residual disease improves the outcome in multiple myeloma. J. Hematol. Oncol. 14, 126 (2021).","journal-title":"J. Hematol. Oncol."},{"key":"1017_CR144","doi-asserted-by":"publisher","first-page":"2056","DOI":"10.1038\/leu.2013.166","volume":"27","author":"B Paiva","year":"2013","unstructured":"Paiva, B. et al. A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and long-term disease control. Leukemia 27, 2056\u20132061 (2013).","journal-title":"Leukemia"},{"key":"1017_CR145","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-019-0176-x","volume":"9","author":"P Rodr\u00edguez-Otero","year":"2019","unstructured":"Rodr\u00edguez-Otero, P. et al. Predicting long-term disease control in transplant-ineligible patients with multiple myeloma: impact of an MGUS-like signature. Blood Cancer J. 9, 36 (2019).","journal-title":"Blood Cancer J."},{"key":"1017_CR146","doi-asserted-by":"publisher","first-page":"3019","DOI":"10.1200\/JCO.22.01916","volume":"41","author":"L Burgos","year":"2023","unstructured":"Burgos, L. et al. Definition and clinical significance of the monoclonal gammopathy of undetermined significance-like phenotype in patients with monoclonal gammopathies. J. Clin. Oncol. 41, 3019\u20133031 (2023).","journal-title":"J. Clin. Oncol."},{"key":"1017_CR147","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1182\/blood-2006-07-037077","volume":"109","author":"F Zhan","year":"2007","unstructured":"Zhan, F. et al. Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis. Blood 109, 1692\u20131700 (2007).","journal-title":"Blood"},{"key":"1017_CR148","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1182\/blood-2023-186411","volume":"142","author":"J-J Garc\u00e9s","year":"2023","unstructured":"Garc\u00e9s, J.-J. et al. Biological and clinical significance of undetectable circulating tumor cells (CTCs) in patients (Pts) with multiple myeloma (MM) [abstract]. Blood 142, 646 (2023).","journal-title":"Blood"},{"key":"1017_CR149","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1002\/ajh.25481","volume":"94","author":"MA Tschautscher","year":"2019","unstructured":"Tschautscher, M. A. et al. Prognostic value of minimal residual disease and polyclonal plasma cells in myeloma patients achieving a complete response to therapy. Am. J. Hematol. 94, 751\u2013756 (2019).","journal-title":"Am. J. Hematol."},{"key":"1017_CR150","first-page":"1909","volume":"109","author":"S Lakhwani","year":"2024","unstructured":"Lakhwani, S. et al. Recovery of uninvolved heavy\/light chain pair immunoparesis in newly diagnosed transplant-eligible myeloma patients complements the prognostic value of minimal residual disease detection. Haematologica 109, 1909\u20131917 (2024).","journal-title":"Haematologica"},{"key":"1017_CR151","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1182\/bloodadvances.2017005447","volume":"1","author":"CM Ho","year":"2017","unstructured":"Ho, C. M. et al. Immune signatures associated with improved progression-free and overall survival for myeloma patients treated with AHSCT. Blood Adv. 1, 1056\u20131066 (2017).","journal-title":"Blood Adv."},{"key":"1017_CR152","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1182\/bloodadvances.2021005198","volume":"6","author":"C Botta","year":"2022","unstructured":"Botta, C. et al. FlowCT for the analysis of large immunophenotypic data sets and biomarker discovery in cancer immunology. Blood Adv. 6, 690\u2013703 (2022).","journal-title":"Blood Adv."},{"key":"1017_CR153","doi-asserted-by":"publisher","first-page":"e43","DOI":"10.1111\/bjh.18948","volume":"202","author":"N Correia","year":"2023","unstructured":"Correia, N. et al. Functional and psychological impact of minimal residual disease assessment on patients with multiple myeloma. Br. J. Haematol. 202, e43\u2013e45 (2023).","journal-title":"Br. J. Haematol."}],"container-title":["Nature Reviews Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41571-025-01017-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41571-025-01017-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41571-025-01017-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T12:01:31Z","timestamp":1748347291000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41571-025-01017-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,7]]},"references-count":153,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["1017"],"URL":"https:\/\/doi.org\/10.1038\/s41571-025-01017-x","relation":{},"ISSN":["1759-4774","1759-4782"],"issn-type":[{"value":"1759-4774","type":"print"},{"value":"1759-4782","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,7]]},"assertion":[{"value":"19 March 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"B.P. reports honoraria for lectures from and participation on advisory boards for Adaptive Biotech, Amgen, Bristol Myers Squibb (BMS)\/Celgene, Gilead, GSK, Janssen, Oncopeptides, Roche, Sanofi, Takeda and The Binding Site; has received unrestricted grants from BMS\/Celgene, EngMab, GSK, Roche, Sanofi and Takeda; and has acted as a consultant for BMS\/Celgene, Janssen and Sanofi. Q.S. reports consulting\/advisory roles for AbbVie, BMS, Boehringer Ingelheim, Genmab, Hoosier Cancer Research Network, Kronos Bio, Mirati Therapeutics, Regeneron and Yiviva; speaker honoraria from Chugai Pharmaceutical; and research funding from BMS\/Celgene, Janssen, MPAACT (to their institution), Novartis, Regeneron and Roche\/Genentech. N.P. has received consultancy fees from Amgen, BMS\/Celgene, Janssen and Takeda; research funding from Amgen, BMS\/Celgene, Janssen and Takeda; and honoraria from Amgen, Celgene, Janssen, Takeda and The Binding Site. M.-T.C. has received honoraria from Amgen, Janssen and Sobi. A.O. has received consultancy and speaker fees from Amgen, BD Biosciences and BluePrint Medicines; and research support from BluePrint Medicines. B.G.M.D. reports consultancy roles for Amgen, BMS, Janssen and Takeda. N.C.M. reports consultancy or advisory roles for Adaptive Biotech, Amgen, BMS, Celgene, Janssen, Legend Biotech, Novartis, Pfizer and Takeda; has received honoraria or consultancy fees for serving on advisory boards from Takeda; and owns stock in Oncopep and DCT Pharmaceutical. J.S.-M. reports consulting or advisory roles for AbbVie, Amgen, BMS, Celgene, GSK, HaemaLogiX, Janssen, Karyopharm Therapeutics, MSD, Novartis, Regeneron, Roche, Sanofi, Secura Bio and Takeda.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}